50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
QQQ   274.84 (-0.24%)
AAPL   150.89 (+0.31%)
MSFT   238.63 (+0.30%)
META   137.63 (-1.98%)
GOOGL   98.62 (-0.12%)
AMZN   115.56 (+1.56%)
TSLA   278.44 (+1.13%)
NVDA   123.72 (-1.15%)
NIO   17.88 (+1.36%)
BABA   79.36 (+0.71%)
AMD   66.76 (-1.77%)
T   15.69 (-2.00%)
MU   49.11 (-1.98%)
CGC   2.77 (-2.46%)
F   12.05 (-2.11%)
GE   64.76 (+0.33%)
DIS   98.78 (-0.72%)
AMC   7.05 (-11.76%)
PYPL   85.28 (-1.94%)
PFE   43.89 (-0.43%)
NFLX   223.88 (-1.12%)
QQQ   274.84 (-0.24%)
AAPL   150.89 (+0.31%)
MSFT   238.63 (+0.30%)
META   137.63 (-1.98%)
GOOGL   98.62 (-0.12%)
AMZN   115.56 (+1.56%)
TSLA   278.44 (+1.13%)
NVDA   123.72 (-1.15%)
NIO   17.88 (+1.36%)
BABA   79.36 (+0.71%)
AMD   66.76 (-1.77%)
T   15.69 (-2.00%)
MU   49.11 (-1.98%)
CGC   2.77 (-2.46%)
F   12.05 (-2.11%)
GE   64.76 (+0.33%)
DIS   98.78 (-0.72%)
AMC   7.05 (-11.76%)
PYPL   85.28 (-1.94%)
PFE   43.89 (-0.43%)
NFLX   223.88 (-1.12%)
QQQ   274.84 (-0.24%)
AAPL   150.89 (+0.31%)
MSFT   238.63 (+0.30%)
META   137.63 (-1.98%)
GOOGL   98.62 (-0.12%)
AMZN   115.56 (+1.56%)
TSLA   278.44 (+1.13%)
NVDA   123.72 (-1.15%)
NIO   17.88 (+1.36%)
BABA   79.36 (+0.71%)
AMD   66.76 (-1.77%)
T   15.69 (-2.00%)
MU   49.11 (-1.98%)
CGC   2.77 (-2.46%)
F   12.05 (-2.11%)
GE   64.76 (+0.33%)
DIS   98.78 (-0.72%)
AMC   7.05 (-11.76%)
PYPL   85.28 (-1.94%)
PFE   43.89 (-0.43%)
NFLX   223.88 (-1.12%)
QQQ   274.84 (-0.24%)
AAPL   150.89 (+0.31%)
MSFT   238.63 (+0.30%)
META   137.63 (-1.98%)
GOOGL   98.62 (-0.12%)
AMZN   115.56 (+1.56%)
TSLA   278.44 (+1.13%)
NVDA   123.72 (-1.15%)
NIO   17.88 (+1.36%)
BABA   79.36 (+0.71%)
AMD   66.76 (-1.77%)
T   15.69 (-2.00%)
MU   49.11 (-1.98%)
CGC   2.77 (-2.46%)
F   12.05 (-2.11%)
GE   64.76 (+0.33%)
DIS   98.78 (-0.72%)
AMC   7.05 (-11.76%)
PYPL   85.28 (-1.94%)
PFE   43.89 (-0.43%)
NFLX   223.88 (-1.12%)
NASDAQ:CASI

CASI Pharmaceuticals - CASI Stock Forecast, Price & News

$2.62
-0.75 (-22.26%)
(As of 09/23/2022 03:59 PM ET)
Add
Compare
Today's Range
$2.62
$3.13
50-Day Range
$2.36
$4.69
52-Week Range
$2.24
$12.70
Volume
5,917 shs
Average Volume
117,784 shs
Market Capitalization
$35.65 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.50

CASI Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
529.8% Upside
$16.50 Price Target
Short Interest
Healthy
1.18% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.84
Upright™ Environmental Score
News Sentiment
0.94mentions of CASI Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$1.02 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($2.26) to ($0.72) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.83 out of 5 stars

Medical Sector

49th out of 1,069 stocks

Biological Products, Except Diagnostic Industry

5th out of 171 stocks

CASI stock logo

About CASI Pharmaceuticals (NASDAQ:CASI) Stock

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's product pipeline includes CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL); BI-1206 that is in Phase I/II trial in combination with anti-PD1 therapy Keytruda for solid tumors, and in a Phase I/IIa trial in combination with MabThera (rituximab) in patients with relapsed/refractory NHL; and CB-5339, which is in Phase I clinical trial for acute myeloid leukemia and myelodysplastic syndrome. Its product pipeline also comprises CID-103 for the treatment of patients with multiple myeloma; Thiotepa, which has multiple indications including use as a conditioning treatment for various allogeneic haemopoietic stem cell transplants; and Octreotide long acting injectable formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumors. The company has licensing agreements with Juventas Cell Therapy Ltd; BioInvent International AB; Black Belt Therapeutics Limited; and Cleave Therapeutics, Inc. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Rockville, Maryland.

Receive CASI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CASI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CASI Stock News Headlines

Wednesday 9/7 Insider Buying Report: JELD, CASI
CASI Pharmaceuticals Inc
CASI PHARMACEUTICALS ANNOUNCES REVERSE STOCK SPLIT
CASI Pharmaceuticals earnings preview: what to expect
See More Headlines
Receive CASI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CASI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CASI Company Calendar

Last Earnings
11/12/2021
Today
9/26/2022
Next Earnings (Estimated)
11/11/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CASI
Employees
176
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$16.50
High Stock Price Forecast
$21.00
Low Stock Price Forecast
$12.00
Forecasted Upside/Downside
+529.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-36,650,000.00
Pretax Margin
-89.69%

Debt

Sales & Book Value

Annual Sales
$30.17 million
Book Value
$6.04 per share

Miscellaneous

Free Float
9,988,000
Market Cap
$35.65 million
Optionable
Not Optionable
Beta
0.45

Key Executives

  • Dr. Wei-Wu He Ph.D. (Age 57)
    Chairman & CEO
    Comp: $565.36k
  • Dr. Wei Zhang Ph.D. (Age 63)
    Pres & Principal Financial Officer
    Comp: $1.13M
  • Ms. Sara B. Capitelli CPA (Age 56)
    VP of Fin.
  • Dr. James E. Goldschmidt Ph.D.
    Chief Bus. Devel. Officer
  • Ms. Amanda Cui
    VP & Global Controller













CASI Stock - Frequently Asked Questions

Should I buy or sell CASI Pharmaceuticals stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CASI Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CASI shares.
View CASI analyst ratings
or view top-rated stocks.

What is CASI Pharmaceuticals' stock price forecast for 2022?

2 Wall Street analysts have issued 12 month price targets for CASI Pharmaceuticals' stock. Their CASI share price forecasts range from $12.00 to $21.00. On average, they anticipate the company's stock price to reach $16.50 in the next twelve months. This suggests a possible upside of 529.8% from the stock's current price.
View analysts price targets for CASI
or view top-rated stocks among Wall Street analysts.

How have CASI shares performed in 2022?

CASI Pharmaceuticals' stock was trading at $8.00 at the beginning of the year. Since then, CASI shares have decreased by 67.3% and is now trading at $2.62.
View the best growth stocks for 2022 here
.

When is CASI Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, November 11th 2022.
View our CASI earnings forecast
.

How were CASI Pharmaceuticals' earnings last quarter?

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) released its quarterly earnings data on Friday, November, 12th. The biotechnology company reported ($0.70) earnings per share for the quarter, missing the consensus estimate of ($0.60) by $0.10. The biotechnology company earned $8.11 million during the quarter, compared to analyst estimates of $7.77 million. CASI Pharmaceuticals had a negative trailing twelve-month return on equity of 41.02% and a negative net margin of 91.97%. During the same quarter last year, the firm earned ($1.40) EPS.

When did CASI Pharmaceuticals' stock split?

Shares of CASI Pharmaceuticals reverse split on Wednesday, June 1st 2022. The 1-10 reverse split was announced on Wednesday, June 1st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 1st 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of CASI Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CASI Pharmaceuticals investors own include NVIDIA (NVDA), OPKO Health (OPK), Caladrius Biosciences (CLBS), Overstock.com (OSTK), Riot Blockchain (RIOT), Boeing (BA), Enphase Energy (ENPH), Catalyst Pharmaceuticals (CPRX), Pure Storage (PSTG) and QUALCOMM (QCOM).

What is CASI Pharmaceuticals' stock symbol?

CASI Pharmaceuticals trades on the NASDAQ under the ticker symbol "CASI."

Who are CASI Pharmaceuticals' major shareholders?

CASI Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Federated Hermes Inc. (7.46%), Wellington Shields Capital Management LLC (1.57%), Wellington Shields & Co. LLC (1.07%), Ikarian Capital LLC (0.97%), State Street Corp (0.26%) and Bailard Inc. (0.23%). Insiders that own company stock include James Huang, Larry Zhang, Weihao Xu and Wei-Wu He.
View institutional ownership trends
.

How do I buy shares of CASI Pharmaceuticals?

Shares of CASI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CASI Pharmaceuticals' stock price today?

One share of CASI stock can currently be purchased for approximately $2.62.

How much money does CASI Pharmaceuticals make?

CASI Pharmaceuticals (NASDAQ:CASI) has a market capitalization of $35.65 million and generates $30.17 million in revenue each year. The biotechnology company earns $-36,650,000.00 in net income (profit) each year or ($2.26) on an earnings per share basis.

How many employees does CASI Pharmaceuticals have?

The company employs 176 workers across the globe.

How can I contact CASI Pharmaceuticals?

CASI Pharmaceuticals' mailing address is 9620 MEDICAL CENTER DR STE 300, ROCKVILLE MD, 20850. The official website for the company is www.casipharmaceuticals.com. The biotechnology company can be reached via phone at (240) 864-2600, via email at ir@casipharmaceuticals.com, or via fax at 301-315-2437.

This page (NASDAQ:CASI) was last updated on 9/26/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.